The use of peptones as medium additives for the production of a recombinant therapeutic protein in high density perfusion cultures of mammalian cells

被引:102
作者
Heidemann, R [1 ]
Zhang, C [1 ]
Qi, HS [1 ]
Larrick Rule, J [1 ]
Rozales, C [1 ]
Park, S [1 ]
Chuppa, S [1 ]
Ray, M [1 ]
Michaels, J [1 ]
Konstantinov, K [1 ]
Naveh, D [1 ]
机构
[1] Bayer Corp, Berkeley, CA 94701 USA
关键词
animal cell culture; BHK; glycosylation; peptone; perfusion culture; product quality;
D O I
10.1023/A:1008196521213
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Protein hydrolysates as substitutes for serum have been employed by many in cell culture medium formulation, especially with the shift to low protein or protein-free media. More recently, vegetable hydrolysates have also been added as nutritional supplements to fortify the amino acid content in small peptide form for batch and fed-batch fermentations. Several of these new hydrolysates (peptones of soy, rice, wheat gluten etc.) were tested as protein-free medium supplements for the production of a recombinant therapeutic protein. Multiple peptone-supplemented, continuous perfusion bioreactor experiments were conducted, varying dilution rates and basal medium composition over the various runs. Cell specific rates and product quality studies were obtained for the various peptones and compared with peptone-free medium. The potential for peptones to decrease intrinsic and proteolytic degradation of the product was also investigated. It was found that peptones confer a nutritional benefit, especially at low dilution rates, for the recombinant BHK cell line used in this investigation. The specific productivity increased 20-30% compared to the peptone-free controls. However, this benefit was also fully delivered by using fortified medium in place of the peptone-enriched media. Therefore, while peptones may be considered as useful medium additives when development time is limited, their addition may be avoided by systematic medium development if permitted by the time line of the project.
引用
收藏
页码:157 / 167
页数:11
相关论文
共 34 条
[1]  
AMATSUJI Y, 1998, Patent No. 9800521
[2]  
Bonarius HPJ, 1996, BIOTECHNOL BIOENG, V50, P299, DOI 10.1002/(SICI)1097-0290(19960505)50:3<299::AID-BIT9>3.0.CO
[3]  
2-B
[4]   IDENTIFICATION OF A RENAL-CELL LINE THAT CONSTITUTIVELY EXPRESSES THE KIDNEY-SPECIFIC HIGH-AFFINITY H+/PEPTIDE COTRANSPORTER [J].
BRANDSCH, M ;
BRANDSCH, C ;
PRASAD, PD ;
GANAPATHY, V ;
HOPFER, U ;
LEIBACH, FH .
FASEB JOURNAL, 1995, 9 (14) :1489-1496
[5]   H+-PEPTIDE COTRANSPORT IN MADIN-DARBY CANINE KIDNEY-CELLS - EXPRESSION AND CALMODULIN-DEPENDENT REGULATION [J].
BRANDSCH, M ;
GANAPATHY, V ;
LEIBACH, FH .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL FLUID AND ELECTROLYTE PHYSIOLOGY, 1995, 268 (03) :F391-F397
[6]   OPTIMIZATION OF SERUM-FREE FERMENTATION PROCESSES FOR ANTIBODY-PRODUCTION [J].
BUNTEMEYER, H ;
LUTKEMEYER, D ;
LEHMANN, J .
CYTOTECHNOLOGY, 1991, 5 (01) :57-67
[7]  
Chuppa S, 1997, BIOTECHNOL BIOENG, V55, P328, DOI 10.1002/(SICI)1097-0290(19970720)55:2<328::AID-BIT10>3.0.CO
[8]  
2-D
[9]   OBSERVATIONS ON THE INFLUENCE OF GLUTAMINE, ASPARAGINE AND PEPTONE ON GROWTH AND T-PA PRODUCTION OF CHINESE-HAMSTER OVARY (CHO) CELLS [J].
DYRING, C ;
HANSEN, HA ;
EMBORG, C .
CYTOTECHNOLOGY, 1994, 16 (01) :37-42
[10]  
GANAPATHY V, 1983, J BIOL CHEM, V258, P4189